Oligonucleotide (siRNA) · Gene silencing: antithrombin (SERPINC1) · developed by Genzyme
Fitusiran is a double-stranded small interfering RNA that binds antithrombin (AT) messenger RNA and degrades it through RNA interference, reducing plasma AT levels. It is studied in hemophilia, a bleeding disorder, and is given subcutaneously.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Sep 16, 2025). Read the full label for the exact wording, limitations and safety information.
Hemophilia
Updated Nov 1, 2026. Something wrong or missing? Report it on the SNY page.
See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SNY catalysts and pipeline →